ArticleBreast cancer research and treatment2023

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.

Alessio Fiascarelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.